ofa semaglutide lawsuit Files Another Against the FDA, This Time Over FDA faces new lawsuit from

2021 Wegovy (semaglutide) A pivotal moment in obesity treatment, demonstrating unprecedented weight-loss outcomes and changing both clinical practice and public perception

Injection site reactions occurred in 1.9-4.5% of tirzepatide recipients compared to just 0.2% of semaglutide recipients in the SURPASS-2 trial

www.wegovy.com CMS

When to Be Concerned While modest first month results are normal, certain situations warrant discussing with your provider: Severe nausea that prevents eating or drinking Vomiting that doesnt improve after the first week Signs of dehydration Severe abdominal pain No appetite changes at all by week four Most people tolerate Wegovy well, but your provider can help troubleshoot if issues arise

Oral drops therapy that mimics natural GLP-1 to improve appetite control and metabolic efficiency